Results 151 to 160 of about 3,724,194 (363)

A subset of MMR‐proficient colon cancers responds to neoadjuvant immunotherapy

open access: yesMolecular Oncology, EarlyView.
Tan et al. reveal that a distinct subset of early‐stage pMMR colon cancers can respond to neoadjuvant immunotherapy. In the NICHE‐2 trial, responders (26%) were characterized by chromosomal instability, TP53 mutations, and proliferative cell‐cycle programs, whereas nonresponders showed metabolic and stromal reprogramming with TGF‐β‐driven ...
Eleonora Piumatti   +3 more
wiley   +1 more source

Spontaneous onset of cellular markers of inflammation and genome instability during aging in the immune niche of the naturally short-lived turquoise killifish ( Nothobranchius furzeri ) [PDF]

open access: gold, 2023
Gabriele Morabito   +6 more
openalex   +1 more source

Developing evidence‐based, cost‐effective P4 cancer medicine for driving innovation in prevention, therapeutics, patient care and reducing healthcare inequalities

open access: yesMolecular Oncology, EarlyView.
The cancer problem is increasing globally with projections up to the year 2050 showing unfavourable outcomes in terms of incidence and cancer‐related deaths. The main challenges are prevention, improved therapeutics resulting in increased cure rates and enhanced health‐related quality of life.
Ulrik Ringborg   +43 more
wiley   +1 more source

Undenatured type II collagen protects against collagen-induced arthritis by restoring gut-joint homeostasis and immunity

open access: yesCommunications Biology
Oral administration of harmless antigens can induce suppression of reactive immune responses, a process that capitalises on the ability of the gastrointestinal tract to tolerate exposure to food and commensal microbiome without triggering inflammatory ...
Piaopiao Pan   +8 more
doaj   +1 more source

Low-dose AgNPs reduce lung mechanical function and innate immune defense in the absence of cellular toxicity

open access: green, 2015
D. Botelho   +11 more
openalex   +2 more sources

Cell surface interactome analysis identifies TSPAN4 as a negative regulator of PD‐L1 in melanoma

open access: yesMolecular Oncology, EarlyView.
Using cell surface proximity biotinylation, we identified tetraspanin TSPAN4 within the PD‐L1 interactome of melanoma cells. TSPAN4 negatively regulates PD‐L1 expression and lateral mobility by limiting its interaction with CMTM6 and promoting PD‐L1 degradation.
Guus A. Franken   +7 more
wiley   +1 more source

CELLULAR IMMUNITY

open access: yesBacteriological Reviews, 1960
openaire   +2 more sources

Hybrid Model Based On Artificial Immune System And Cellular Automata

open access: green, 2011
Ramin Javadzadeh   +2 more
openalex   +1 more source

Home - About - Disclaimer - Privacy